IL6R and rheumatoid arthritis: TCZ is a recombinant humanized mAb, and its target molecule is the IL6 receptor (IL-6R) approved for RA, systemic juvenile idiopathic arthritis (sJIA), or polyarticular course juvenile idiopathic arthritis (pJIA).